nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—CYP3A4—Bexarotene—hematologic cancer	0.0223	0.0829	CbGbCtD
Cabergoline—CYP3A4—Busulfan—hematologic cancer	0.0207	0.077	CbGbCtD
Cabergoline—CYP3A4—Lomustine—hematologic cancer	0.0207	0.077	CbGbCtD
Cabergoline—CYP3A4—Thiotepa—hematologic cancer	0.0185	0.0687	CbGbCtD
Cabergoline—CYP3A4—Methoxsalen—hematologic cancer	0.0144	0.0534	CbGbCtD
Cabergoline—CYP3A4—Bortezomib—hematologic cancer	0.0137	0.0508	CbGbCtD
Cabergoline—CYP3A4—Daunorubicin—hematologic cancer	0.0131	0.0486	CbGbCtD
Cabergoline—CYP3A4—Cytarabine—hematologic cancer	0.0115	0.0429	CbGbCtD
Cabergoline—CYP3A4—Teniposide—hematologic cancer	0.0114	0.0422	CbGbCtD
Cabergoline—CYP3A4—Ifosfamide—hematologic cancer	0.0105	0.039	CbGbCtD
Cabergoline—CYP3A4—Imatinib—hematologic cancer	0.01	0.0372	CbGbCtD
Cabergoline—CYP3A4—Ruxolitinib—hematologic cancer	0.00943	0.035	CbGbCtD
Cabergoline—CYP3A4—Nilotinib—hematologic cancer	0.0091	0.0338	CbGbCtD
Cabergoline—CYP3A4—Vinorelbine—hematologic cancer	0.00902	0.0335	CbGbCtD
Cabergoline—CYP3A4—Triamcinolone—hematologic cancer	0.00825	0.0307	CbGbCtD
Cabergoline—CYP3A4—Dasatinib—hematologic cancer	0.00804	0.0299	CbGbCtD
Cabergoline—CYP3A4—Mitoxantrone—hematologic cancer	0.00794	0.0295	CbGbCtD
Cabergoline—CYP3A4—Betamethasone—hematologic cancer	0.00708	0.0263	CbGbCtD
Cabergoline—CYP3A4—Prednisolone—hematologic cancer	0.00699	0.026	CbGbCtD
Cabergoline—CYP3A4—Prednisone—hematologic cancer	0.0066	0.0245	CbGbCtD
Cabergoline—CYP3A4—Irinotecan—hematologic cancer	0.00625	0.0232	CbGbCtD
Cabergoline—CYP3A4—Vinblastine—hematologic cancer	0.00556	0.0207	CbGbCtD
Cabergoline—CYP3A4—Vincristine—hematologic cancer	0.00547	0.0203	CbGbCtD
Cabergoline—CYP3A4—Etoposide—hematologic cancer	0.00501	0.0186	CbGbCtD
Cabergoline—CYP3A4—Dexamethasone—hematologic cancer	0.00412	0.0153	CbGbCtD
Cabergoline—CYP3A4—Doxorubicin—hematologic cancer	0.00342	0.0127	CbGbCtD
Cabergoline—DRD5—hematopoietic system—hematologic cancer	0.00102	0.096	CbGeAlD
Cabergoline—DRD4—testis—hematologic cancer	0.000848	0.0799	CbGeAlD
Cabergoline—HTR1A—hematopoietic system—hematologic cancer	0.00051	0.048	CbGeAlD
Cabergoline—HTR7—hematopoietic system—hematologic cancer	0.000487	0.0458	CbGeAlD
Cabergoline—ADRA1A—hematopoietic system—hematologic cancer	0.00047	0.0442	CbGeAlD
Cabergoline—HTR2B—blood—hematologic cancer	0.000377	0.0355	CbGeAlD
Cabergoline—HTR7—gonad—hematologic cancer	0.00037	0.0349	CbGeAlD
Cabergoline—ADRA2A—hematopoietic system—hematologic cancer	0.000357	0.0336	CbGeAlD
Cabergoline—ADRB1—lung—hematologic cancer	0.000345	0.0325	CbGeAlD
Cabergoline—HTR2B—lung—hematologic cancer	0.00033	0.0311	CbGeAlD
Cabergoline—HTR7—blood—hematologic cancer	0.000323	0.0304	CbGeAlD
Cabergoline—ADRA1A—blood—hematologic cancer	0.000311	0.0293	CbGeAlD
Cabergoline—HTR2A—hematopoietic system—hematologic cancer	0.000304	0.0286	CbGeAlD
Cabergoline—ADRA2C—blood—hematologic cancer	0.000297	0.0279	CbGeAlD
Cabergoline—HTR7—lung—hematologic cancer	0.000283	0.0266	CbGeAlD
Cabergoline—CYP3A4—hematopoietic system—hematologic cancer	0.000281	0.0265	CbGeAlD
Cabergoline—ADRA2A—gonad—hematologic cancer	0.000272	0.0256	CbGeAlD
Cabergoline—DRD2—lung—hematologic cancer	0.000267	0.0252	CbGeAlD
Cabergoline—HTR7—testis—hematologic cancer	0.000267	0.0251	CbGeAlD
Cabergoline—ADRA2C—lung—hematologic cancer	0.00026	0.0245	CbGeAlD
Cabergoline—DRD2—testis—hematologic cancer	0.000252	0.0238	CbGeAlD
Cabergoline—ADRA2C—testis—hematologic cancer	0.000245	0.0231	CbGeAlD
Cabergoline—ADRA2A—blood—hematologic cancer	0.000237	0.0223	CbGeAlD
Cabergoline—HTR2A—gonad—hematologic cancer	0.000231	0.0217	CbGeAlD
Cabergoline—HTR2B—lymph node—hematologic cancer	0.000226	0.0213	CbGeAlD
Cabergoline—ADRA2A—lung—hematologic cancer	0.000207	0.0195	CbGeAlD
Cabergoline—HTR2A—blood—hematologic cancer	0.000201	0.0189	CbGeAlD
Cabergoline—ADRA2A—testis—hematologic cancer	0.000196	0.0184	CbGeAlD
Cabergoline—CYP3A4—blood—hematologic cancer	0.000186	0.0175	CbGeAlD
Cabergoline—ADRA2C—lymph node—hematologic cancer	0.000178	0.0167	CbGeAlD
Cabergoline—HTR2A—lung—hematologic cancer	0.000176	0.0166	CbGeAlD
Cabergoline—HTR2A—testis—hematologic cancer	0.000166	0.0157	CbGeAlD
Cabergoline—ADRA2A—lymph node—hematologic cancer	0.000142	0.0134	CbGeAlD
Cabergoline—Nausea—Carmustine—hematologic cancer	7.61e-05	0.000152	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—hematologic cancer	7.6e-05	0.000152	CcSEcCtD
Cabergoline—Vomiting—Irinotecan—hematologic cancer	7.57e-05	0.000151	CcSEcCtD
Cabergoline—Vomiting—Mitoxantrone—hematologic cancer	7.57e-05	0.000151	CcSEcCtD
Cabergoline—Nausea—Alitretinoin—hematologic cancer	7.54e-05	0.000151	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—hematologic cancer	7.53e-05	0.00015	CcSEcCtD
Cabergoline—Hypertension—Prednisone—hematologic cancer	7.51e-05	0.00015	CcSEcCtD
Cabergoline—Rash—Mitoxantrone—hematologic cancer	7.51e-05	0.00015	CcSEcCtD
Cabergoline—Rash—Irinotecan—hematologic cancer	7.51e-05	0.00015	CcSEcCtD
Cabergoline—Dermatitis—Mitoxantrone—hematologic cancer	7.5e-05	0.00015	CcSEcCtD
Cabergoline—Dermatitis—Irinotecan—hematologic cancer	7.5e-05	0.00015	CcSEcCtD
Cabergoline—Headache—Mitoxantrone—hematologic cancer	7.46e-05	0.000149	CcSEcCtD
Cabergoline—Headache—Irinotecan—hematologic cancer	7.46e-05	0.000149	CcSEcCtD
Cabergoline—Nausea—Ifosfamide—hematologic cancer	7.45e-05	0.000149	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Betamethasone—hematologic cancer	7.43e-05	0.000148	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	7.43e-05	0.000148	CcSEcCtD
Cabergoline—Arthralgia—Prednisone—hematologic cancer	7.41e-05	0.000148	CcSEcCtD
Cabergoline—Feeling abnormal—Triamcinolone—hematologic cancer	7.4e-05	0.000148	CcSEcCtD
Cabergoline—Diarrhoea—Cisplatin—hematologic cancer	7.4e-05	0.000148	CcSEcCtD
Cabergoline—Anxiety—Prednisone—hematologic cancer	7.38e-05	0.000147	CcSEcCtD
Cabergoline—Alopecia—Methotrexate—hematologic cancer	7.38e-05	0.000147	CcSEcCtD
Cabergoline—Vomiting—Gemcitabine—hematologic cancer	7.38e-05	0.000147	CcSEcCtD
Cabergoline—Insomnia—Dexamethasone—hematologic cancer	7.37e-05	0.000147	CcSEcCtD
Cabergoline—Insomnia—Betamethasone—hematologic cancer	7.37e-05	0.000147	CcSEcCtD
Cabergoline—Paraesthesia—Betamethasone—hematologic cancer	7.32e-05	0.000146	CcSEcCtD
Cabergoline—Paraesthesia—Dexamethasone—hematologic cancer	7.32e-05	0.000146	CcSEcCtD
Cabergoline—Discomfort—Prednisone—hematologic cancer	7.32e-05	0.000146	CcSEcCtD
Cabergoline—Rash—Gemcitabine—hematologic cancer	7.31e-05	0.000146	CcSEcCtD
Cabergoline—Dermatitis—Gemcitabine—hematologic cancer	7.31e-05	0.000146	CcSEcCtD
Cabergoline—Hypersensitivity—Etoposide—hematologic cancer	7.3e-05	0.000146	CcSEcCtD
Cabergoline—Headache—Gemcitabine—hematologic cancer	7.27e-05	0.000145	CcSEcCtD
Cabergoline—Nausea—Vincristine—hematologic cancer	7.26e-05	0.000145	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—hematologic cancer	7.25e-05	0.000145	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—hematologic cancer	7.25e-05	0.000145	CcSEcCtD
Cabergoline—Hypersensitivity—Prednisolone—hematologic cancer	7.2e-05	0.000144	CcSEcCtD
Cabergoline—Dyspepsia—Betamethasone—hematologic cancer	7.18e-05	0.000143	CcSEcCtD
Cabergoline—Dyspepsia—Dexamethasone—hematologic cancer	7.18e-05	0.000143	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—hematologic cancer	7.12e-05	0.000142	CcSEcCtD
Cabergoline—Asthenia—Etoposide—hematologic cancer	7.11e-05	0.000142	CcSEcCtD
Cabergoline—Oedema—Prednisone—hematologic cancer	7.1e-05	0.000142	CcSEcCtD
Cabergoline—Decreased appetite—Dexamethasone—hematologic cancer	7.09e-05	0.000142	CcSEcCtD
Cabergoline—Decreased appetite—Betamethasone—hematologic cancer	7.09e-05	0.000142	CcSEcCtD
Cabergoline—Nausea—Mitoxantrone—hematologic cancer	7.07e-05	0.000141	CcSEcCtD
Cabergoline—Nausea—Irinotecan—hematologic cancer	7.07e-05	0.000141	CcSEcCtD
Cabergoline—Back pain—Methotrexate—hematologic cancer	7.03e-05	0.00014	CcSEcCtD
Cabergoline—Fatigue—Dexamethasone—hematologic cancer	7.03e-05	0.00014	CcSEcCtD
Cabergoline—Fatigue—Betamethasone—hematologic cancer	7.03e-05	0.00014	CcSEcCtD
Cabergoline—Pruritus—Etoposide—hematologic cancer	7.01e-05	0.00014	CcSEcCtD
Cabergoline—Shock—Prednisone—hematologic cancer	6.99e-05	0.00014	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—hematologic cancer	6.98e-05	0.000139	CcSEcCtD
Cabergoline—Pain—Betamethasone—hematologic cancer	6.97e-05	0.000139	CcSEcCtD
Cabergoline—Pain—Dexamethasone—hematologic cancer	6.97e-05	0.000139	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—hematologic cancer	6.97e-05	0.000139	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—hematologic cancer	6.91e-05	0.000138	CcSEcCtD
Cabergoline—Nausea—Gemcitabine—hematologic cancer	6.89e-05	0.000138	CcSEcCtD
Cabergoline—Vomiting—Cisplatin—hematologic cancer	6.87e-05	0.000137	CcSEcCtD
Cabergoline—Hyperhidrosis—Prednisone—hematologic cancer	6.86e-05	0.000137	CcSEcCtD
Cabergoline—Rash—Cisplatin—hematologic cancer	6.82e-05	0.000136	CcSEcCtD
Cabergoline—Dermatitis—Cisplatin—hematologic cancer	6.81e-05	0.000136	CcSEcCtD
Cabergoline—Diarrhoea—Etoposide—hematologic cancer	6.78e-05	0.000135	CcSEcCtD
Cabergoline—Anorexia—Prednisone—hematologic cancer	6.77e-05	0.000135	CcSEcCtD
Cabergoline—Ill-defined disorder—Methotrexate—hematologic cancer	6.75e-05	0.000135	CcSEcCtD
Cabergoline—Feeling abnormal—Betamethasone—hematologic cancer	6.72e-05	0.000134	CcSEcCtD
Cabergoline—Feeling abnormal—Dexamethasone—hematologic cancer	6.72e-05	0.000134	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—hematologic cancer	6.71e-05	0.000134	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—hematologic cancer	6.7e-05	0.000134	CcSEcCtD
Cabergoline—Tension—Epirubicin—hematologic cancer	6.68e-05	0.000133	CcSEcCtD
Cabergoline—Gastrointestinal pain—Betamethasone—hematologic cancer	6.67e-05	0.000133	CcSEcCtD
Cabergoline—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.67e-05	0.000133	CcSEcCtD
Cabergoline—Hypersensitivity—Triamcinolone—hematologic cancer	6.62e-05	0.000132	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—hematologic cancer	6.61e-05	0.000132	CcSEcCtD
Cabergoline—Back pain—Epirubicin—hematologic cancer	6.58e-05	0.000131	CcSEcCtD
Cabergoline—Malaise—Methotrexate—hematologic cancer	6.56e-05	0.000131	CcSEcCtD
Cabergoline—Dizziness—Etoposide—hematologic cancer	6.55e-05	0.000131	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—hematologic cancer	6.54e-05	0.000131	CcSEcCtD
Cabergoline—Vertigo—Methotrexate—hematologic cancer	6.53e-05	0.00013	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.47e-05	0.000129	CcSEcCtD
Cabergoline—Dizziness—Prednisolone—hematologic cancer	6.46e-05	0.000129	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—hematologic cancer	6.46e-05	0.000129	CcSEcCtD
Cabergoline—Asthenia—Triamcinolone—hematologic cancer	6.45e-05	0.000129	CcSEcCtD
Cabergoline—Abdominal pain—Dexamethasone—hematologic cancer	6.44e-05	0.000129	CcSEcCtD
Cabergoline—Abdominal pain—Betamethasone—hematologic cancer	6.44e-05	0.000129	CcSEcCtD
Cabergoline—Nausea—Cisplatin—hematologic cancer	6.42e-05	0.000128	CcSEcCtD
Cabergoline—Insomnia—Prednisone—hematologic cancer	6.42e-05	0.000128	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—hematologic cancer	6.39e-05	0.000128	CcSEcCtD
Cabergoline—Paraesthesia—Prednisone—hematologic cancer	6.38e-05	0.000127	CcSEcCtD
Cabergoline—Pruritus—Triamcinolone—hematologic cancer	6.36e-05	0.000127	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—hematologic cancer	6.31e-05	0.000126	CcSEcCtD
Cabergoline—Vomiting—Etoposide—hematologic cancer	6.3e-05	0.000126	CcSEcCtD
Cabergoline—Dyspepsia—Prednisone—hematologic cancer	6.25e-05	0.000125	CcSEcCtD
Cabergoline—Rash—Etoposide—hematologic cancer	6.25e-05	0.000125	CcSEcCtD
Cabergoline—Dermatitis—Etoposide—hematologic cancer	6.24e-05	0.000125	CcSEcCtD
Cabergoline—Headache—Etoposide—hematologic cancer	6.21e-05	0.000124	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—hematologic cancer	6.2e-05	0.000124	CcSEcCtD
Cabergoline—Arthralgia—Methotrexate—hematologic cancer	6.19e-05	0.000124	CcSEcCtD
Cabergoline—Tension—Doxorubicin—hematologic cancer	6.18e-05	0.000123	CcSEcCtD
Cabergoline—Decreased appetite—Prednisone—hematologic cancer	6.17e-05	0.000123	CcSEcCtD
Cabergoline—Rash—Prednisolone—hematologic cancer	6.16e-05	0.000123	CcSEcCtD
Cabergoline—Dermatitis—Prednisolone—hematologic cancer	6.15e-05	0.000123	CcSEcCtD
Cabergoline—Malaise—Epirubicin—hematologic cancer	6.14e-05	0.000123	CcSEcCtD
Cabergoline—Fatigue—Prednisone—hematologic cancer	6.12e-05	0.000122	CcSEcCtD
Cabergoline—Headache—Prednisolone—hematologic cancer	6.12e-05	0.000122	CcSEcCtD
Cabergoline—Discomfort—Methotrexate—hematologic cancer	6.12e-05	0.000122	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—hematologic cancer	6.11e-05	0.000122	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—hematologic cancer	6.11e-05	0.000122	CcSEcCtD
Cabergoline—Syncope—Epirubicin—hematologic cancer	6.1e-05	0.000122	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—hematologic cancer	6.09e-05	0.000122	CcSEcCtD
Cabergoline—Constipation—Prednisone—hematologic cancer	6.07e-05	0.000121	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—hematologic cancer	6.05e-05	0.000121	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—hematologic cancer	6.01e-05	0.00012	CcSEcCtD
Cabergoline—Confusional state—Methotrexate—hematologic cancer	5.98e-05	0.000119	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—hematologic cancer	5.98e-05	0.000119	CcSEcCtD
Cabergoline—Dizziness—Triamcinolone—hematologic cancer	5.94e-05	0.000119	CcSEcCtD
Cabergoline—Nausea—Etoposide—hematologic cancer	5.88e-05	0.000118	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—hematologic cancer	5.87e-05	0.000117	CcSEcCtD
Cabergoline—Feeling abnormal—Prednisone—hematologic cancer	5.85e-05	0.000117	CcSEcCtD
Cabergoline—Asthenia—Betamethasone—hematologic cancer	5.85e-05	0.000117	CcSEcCtD
Cabergoline—Asthenia—Dexamethasone—hematologic cancer	5.85e-05	0.000117	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—hematologic cancer	5.84e-05	0.000117	CcSEcCtD
Cabergoline—Gastrointestinal pain—Prednisone—hematologic cancer	5.81e-05	0.000116	CcSEcCtD
Cabergoline—Nausea—Prednisolone—hematologic cancer	5.8e-05	0.000116	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—hematologic cancer	5.79e-05	0.000116	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—hematologic cancer	5.77e-05	0.000115	CcSEcCtD
Cabergoline—Pruritus—Dexamethasone—hematologic cancer	5.77e-05	0.000115	CcSEcCtD
Cabergoline—Pruritus—Betamethasone—hematologic cancer	5.77e-05	0.000115	CcSEcCtD
Cabergoline—Hyperhidrosis—Methotrexate—hematologic cancer	5.74e-05	0.000115	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—hematologic cancer	5.72e-05	0.000114	CcSEcCtD
Cabergoline—Vomiting—Triamcinolone—hematologic cancer	5.71e-05	0.000114	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—hematologic cancer	5.68e-05	0.000113	CcSEcCtD
Cabergoline—Rash—Triamcinolone—hematologic cancer	5.67e-05	0.000113	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—hematologic cancer	5.66e-05	0.000113	CcSEcCtD
Cabergoline—Dermatitis—Triamcinolone—hematologic cancer	5.66e-05	0.000113	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—hematologic cancer	5.66e-05	0.000113	CcSEcCtD
Cabergoline—Anorexia—Methotrexate—hematologic cancer	5.66e-05	0.000113	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—hematologic cancer	5.65e-05	0.000113	CcSEcCtD
Cabergoline—Headache—Triamcinolone—hematologic cancer	5.63e-05	0.000112	CcSEcCtD
Cabergoline—Abdominal pain—Prednisone—hematologic cancer	5.61e-05	0.000112	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—hematologic cancer	5.6e-05	0.000112	CcSEcCtD
Cabergoline—Diarrhoea—Dexamethasone—hematologic cancer	5.58e-05	0.000111	CcSEcCtD
Cabergoline—Diarrhoea—Betamethasone—hematologic cancer	5.58e-05	0.000111	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—hematologic cancer	5.56e-05	0.000111	CcSEcCtD
Cabergoline—Oedema—Epirubicin—hematologic cancer	5.55e-05	0.000111	CcSEcCtD
Cabergoline—Hypotension—Methotrexate—hematologic cancer	5.54e-05	0.000111	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—hematologic cancer	5.53e-05	0.000111	CcSEcCtD
Cabergoline—Shock—Epirubicin—hematologic cancer	5.46e-05	0.000109	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—hematologic cancer	5.44e-05	0.000109	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.41e-05	0.000108	CcSEcCtD
Cabergoline—Dizziness—Dexamethasone—hematologic cancer	5.39e-05	0.000108	CcSEcCtD
Cabergoline—Dizziness—Betamethasone—hematologic cancer	5.39e-05	0.000108	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—hematologic cancer	5.37e-05	0.000107	CcSEcCtD
Cabergoline—Insomnia—Methotrexate—hematologic cancer	5.37e-05	0.000107	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—hematologic cancer	5.36e-05	0.000107	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—hematologic cancer	5.34e-05	0.000107	CcSEcCtD
Cabergoline—Nausea—Triamcinolone—hematologic cancer	5.34e-05	0.000107	CcSEcCtD
Cabergoline—Paraesthesia—Methotrexate—hematologic cancer	5.33e-05	0.000106	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—hematologic cancer	5.3e-05	0.000106	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—hematologic cancer	5.29e-05	0.000106	CcSEcCtD
Cabergoline—Dyspnoea—Methotrexate—hematologic cancer	5.29e-05	0.000106	CcSEcCtD
Cabergoline—Somnolence—Methotrexate—hematologic cancer	5.27e-05	0.000105	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—hematologic cancer	5.24e-05	0.000105	CcSEcCtD
Cabergoline—Hypersensitivity—Prednisone—hematologic cancer	5.23e-05	0.000104	CcSEcCtD
Cabergoline—Dyspepsia—Methotrexate—hematologic cancer	5.22e-05	0.000104	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—hematologic cancer	5.19e-05	0.000104	CcSEcCtD
Cabergoline—Vomiting—Betamethasone—hematologic cancer	5.18e-05	0.000104	CcSEcCtD
Cabergoline—Vomiting—Dexamethasone—hematologic cancer	5.18e-05	0.000104	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—hematologic cancer	5.18e-05	0.000103	CcSEcCtD
Cabergoline—Decreased appetite—Methotrexate—hematologic cancer	5.16e-05	0.000103	CcSEcCtD
Cabergoline—Rash—Betamethasone—hematologic cancer	5.14e-05	0.000103	CcSEcCtD
Cabergoline—Rash—Dexamethasone—hematologic cancer	5.14e-05	0.000103	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—hematologic cancer	5.14e-05	0.000103	CcSEcCtD
Cabergoline—Dermatitis—Betamethasone—hematologic cancer	5.14e-05	0.000103	CcSEcCtD
Cabergoline—Dermatitis—Dexamethasone—hematologic cancer	5.14e-05	0.000103	CcSEcCtD
Cabergoline—Fatigue—Methotrexate—hematologic cancer	5.12e-05	0.000102	CcSEcCtD
Cabergoline—Headache—Betamethasone—hematologic cancer	5.11e-05	0.000102	CcSEcCtD
Cabergoline—Headache—Dexamethasone—hematologic cancer	5.11e-05	0.000102	CcSEcCtD
Cabergoline—Asthenia—Prednisone—hematologic cancer	5.09e-05	0.000102	CcSEcCtD
Cabergoline—Pain—Methotrexate—hematologic cancer	5.07e-05	0.000101	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.06e-05	0.000101	CcSEcCtD
Cabergoline—Shock—Doxorubicin—hematologic cancer	5.05e-05	0.000101	CcSEcCtD
Cabergoline—Pruritus—Prednisone—hematologic cancer	5.02e-05	0.0001	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—hematologic cancer	5.02e-05	0.0001	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—hematologic cancer	4.99e-05	9.96e-05	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—hematologic cancer	4.97e-05	9.92e-05	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—hematologic cancer	4.95e-05	9.89e-05	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—hematologic cancer	4.94e-05	9.86e-05	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—hematologic cancer	4.9e-05	9.78e-05	CcSEcCtD
Cabergoline—Feeling abnormal—Methotrexate—hematologic cancer	4.89e-05	9.77e-05	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—hematologic cancer	4.89e-05	9.76e-05	CcSEcCtD
Cabergoline—Diarrhoea—Prednisone—hematologic cancer	4.86e-05	9.7e-05	CcSEcCtD
Cabergoline—Gastrointestinal pain—Methotrexate—hematologic cancer	4.85e-05	9.69e-05	CcSEcCtD
Cabergoline—Nausea—Betamethasone—hematologic cancer	4.84e-05	9.67e-05	CcSEcCtD
Cabergoline—Nausea—Dexamethasone—hematologic cancer	4.84e-05	9.67e-05	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—hematologic cancer	4.83e-05	9.64e-05	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—hematologic cancer	4.8e-05	9.59e-05	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—hematologic cancer	4.79e-05	9.56e-05	CcSEcCtD
Cabergoline—Pain—Epirubicin—hematologic cancer	4.75e-05	9.48e-05	CcSEcCtD
Cabergoline—Constipation—Epirubicin—hematologic cancer	4.75e-05	9.48e-05	CcSEcCtD
Cabergoline—Dizziness—Prednisone—hematologic cancer	4.69e-05	9.38e-05	CcSEcCtD
Cabergoline—Abdominal pain—Methotrexate—hematologic cancer	4.69e-05	9.37e-05	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.68e-05	9.35e-05	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—hematologic cancer	4.65e-05	9.28e-05	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—hematologic cancer	4.61e-05	9.21e-05	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—hematologic cancer	4.58e-05	9.15e-05	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—hematologic cancer	4.58e-05	9.14e-05	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—hematologic cancer	4.57e-05	9.12e-05	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—hematologic cancer	4.54e-05	9.07e-05	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—hematologic cancer	4.52e-05	9.03e-05	CcSEcCtD
Cabergoline—Vomiting—Prednisone—hematologic cancer	4.51e-05	9.02e-05	CcSEcCtD
Cabergoline—Rash—Prednisone—hematologic cancer	4.48e-05	8.94e-05	CcSEcCtD
Cabergoline—Dermatitis—Prednisone—hematologic cancer	4.47e-05	8.93e-05	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—hematologic cancer	4.47e-05	8.92e-05	CcSEcCtD
Cabergoline—Headache—Prednisone—hematologic cancer	4.45e-05	8.88e-05	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—hematologic cancer	4.43e-05	8.85e-05	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—hematologic cancer	4.39e-05	8.78e-05	CcSEcCtD
Cabergoline—Pain—Doxorubicin—hematologic cancer	4.39e-05	8.78e-05	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—hematologic cancer	4.39e-05	8.77e-05	CcSEcCtD
Cabergoline—Hypersensitivity—Methotrexate—hematologic cancer	4.37e-05	8.73e-05	CcSEcCtD
Cabergoline—Asthenia—Methotrexate—hematologic cancer	4.26e-05	8.5e-05	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—hematologic cancer	4.23e-05	8.46e-05	CcSEcCtD
Cabergoline—Nausea—Prednisone—hematologic cancer	4.22e-05	8.42e-05	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.2e-05	8.39e-05	CcSEcCtD
Cabergoline—Pruritus—Methotrexate—hematologic cancer	4.2e-05	8.38e-05	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—hematologic cancer	4.09e-05	8.17e-05	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—hematologic cancer	4.06e-05	8.11e-05	CcSEcCtD
Cabergoline—Diarrhoea—Methotrexate—hematologic cancer	4.06e-05	8.11e-05	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—hematologic cancer	3.98e-05	7.96e-05	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—hematologic cancer	3.93e-05	7.85e-05	CcSEcCtD
Cabergoline—Dizziness—Methotrexate—hematologic cancer	3.92e-05	7.84e-05	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—hematologic cancer	3.8e-05	7.59e-05	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—hematologic cancer	3.79e-05	7.56e-05	CcSEcCtD
Cabergoline—Vomiting—Methotrexate—hematologic cancer	3.77e-05	7.54e-05	CcSEcCtD
Cabergoline—Rash—Methotrexate—hematologic cancer	3.74e-05	7.47e-05	CcSEcCtD
Cabergoline—Dermatitis—Methotrexate—hematologic cancer	3.74e-05	7.47e-05	CcSEcCtD
Cabergoline—Headache—Methotrexate—hematologic cancer	3.72e-05	7.42e-05	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—hematologic cancer	3.69e-05	7.36e-05	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—hematologic cancer	3.67e-05	7.33e-05	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—hematologic cancer	3.64e-05	7.26e-05	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—hematologic cancer	3.53e-05	7.05e-05	CcSEcCtD
Cabergoline—Nausea—Methotrexate—hematologic cancer	3.52e-05	7.04e-05	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—hematologic cancer	3.52e-05	7.02e-05	CcSEcCtD
Cabergoline—Rash—Epirubicin—hematologic cancer	3.5e-05	6.99e-05	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—hematologic cancer	3.5e-05	6.99e-05	CcSEcCtD
Cabergoline—Headache—Epirubicin—hematologic cancer	3.48e-05	6.95e-05	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—hematologic cancer	3.4e-05	6.79e-05	CcSEcCtD
Cabergoline—Nausea—Epirubicin—hematologic cancer	3.3e-05	6.59e-05	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—hematologic cancer	3.27e-05	6.52e-05	CcSEcCtD
Cabergoline—Rash—Doxorubicin—hematologic cancer	3.24e-05	6.47e-05	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—hematologic cancer	3.24e-05	6.46e-05	CcSEcCtD
Cabergoline—Headache—Doxorubicin—hematologic cancer	3.22e-05	6.43e-05	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—hematologic cancer	3.05e-05	6.1e-05	CcSEcCtD
Cabergoline—DRD2—Signaling Pathways—CASP3—hematologic cancer	3.83e-06	1.75e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL2—hematologic cancer	3.83e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NRAS—hematologic cancer	3.83e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3.82e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3.81e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—hematologic cancer	3.81e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	3.81e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—SRC—hematologic cancer	3.8e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	3.8e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	3.8e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	3.79e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	3.79e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EP300—hematologic cancer	3.79e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.78e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—hematologic cancer	3.78e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—hematologic cancer	3.77e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	3.77e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—hematologic cancer	3.77e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—hematologic cancer	3.75e-06	1.71e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—hematologic cancer	3.75e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—hematologic cancer	3.75e-06	1.71e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—hematologic cancer	3.74e-06	1.7e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	3.74e-06	1.7e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—hematologic cancer	3.73e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	3.73e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	3.73e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	3.73e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EP300—hematologic cancer	3.73e-06	1.7e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—JUN—hematologic cancer	3.72e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	3.7e-06	1.69e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	3.69e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—hematologic cancer	3.69e-06	1.68e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	3.69e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—hematologic cancer	3.68e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—EP300—hematologic cancer	3.68e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—hematologic cancer	3.67e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—hematologic cancer	3.67e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	3.67e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—hematologic cancer	3.67e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	3.66e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—JUN—hematologic cancer	3.66e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—hematologic cancer	3.66e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—hematologic cancer	3.66e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—hematologic cancer	3.65e-06	1.66e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NRAS—hematologic cancer	3.64e-06	1.66e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.64e-06	1.66e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	3.63e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—hematologic cancer	3.62e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—hematologic cancer	3.62e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—hematologic cancer	3.61e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	3.61e-06	1.65e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—hematologic cancer	3.61e-06	1.64e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	3.61e-06	1.64e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—hematologic cancer	3.6e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	3.59e-06	1.64e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—hematologic cancer	3.59e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—JUN—hematologic cancer	3.59e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	3.58e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	3.58e-06	1.63e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	3.57e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—hematologic cancer	3.56e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	3.56e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	3.56e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	3.55e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	3.55e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—hematologic cancer	3.54e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	3.54e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—hematologic cancer	3.53e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	3.53e-06	1.61e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK8—hematologic cancer	3.52e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	3.52e-06	1.6e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—hematologic cancer	3.51e-06	1.6e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—hematologic cancer	3.51e-06	1.6e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	3.5e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.5e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	3.49e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.49e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—hematologic cancer	3.49e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	3.49e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	3.48e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	3.48e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	3.47e-06	1.58e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	3.47e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.46e-06	1.58e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—hematologic cancer	3.46e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—hematologic cancer	3.46e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	3.46e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—hematologic cancer	3.45e-06	1.57e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.44e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—hematologic cancer	3.44e-06	1.56e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EP300—hematologic cancer	3.43e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	3.43e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—hematologic cancer	3.43e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	3.41e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—hematologic cancer	3.41e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	3.4e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	3.39e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	3.39e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.39e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	3.38e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.38e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EP300—hematologic cancer	3.38e-06	1.54e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	3.37e-06	1.53e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—hematologic cancer	3.36e-06	1.53e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—hematologic cancer	3.35e-06	1.52e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—hematologic cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—JUN—hematologic cancer	3.33e-06	1.52e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	3.32e-06	1.51e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	3.32e-06	1.51e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—hematologic cancer	3.31e-06	1.51e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EP300—hematologic cancer	3.31e-06	1.51e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—hematologic cancer	3.3e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—hematologic cancer	3.3e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—hematologic cancer	3.29e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	3.29e-06	1.5e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—hematologic cancer	3.29e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	3.26e-06	1.49e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—hematologic cancer	3.26e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—hematologic cancer	3.25e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—hematologic cancer	3.25e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	3.24e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	3.23e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	3.22e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—hematologic cancer	3.22e-06	1.47e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—hematologic cancer	3.22e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—hematologic cancer	3.22e-06	1.46e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—hematologic cancer	3.21e-06	1.46e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—hematologic cancer	3.21e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—hematologic cancer	3.21e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	3.2e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—hematologic cancer	3.19e-06	1.45e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—hematologic cancer	3.17e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—hematologic cancer	3.17e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—hematologic cancer	3.16e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—hematologic cancer	3.16e-06	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	3.15e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—hematologic cancer	3.15e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	3.15e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	3.13e-06	1.43e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—hematologic cancer	3.13e-06	1.43e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—hematologic cancer	3.11e-06	1.42e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	3.1e-06	1.41e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—hematologic cancer	3.1e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	3.1e-06	1.41e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—hematologic cancer	3.08e-06	1.4e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EP300—hematologic cancer	3.07e-06	1.4e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	3.07e-06	1.4e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—hematologic cancer	3.07e-06	1.4e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—hematologic cancer	3.05e-06	1.39e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	3.05e-06	1.39e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	3.03e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	3.03e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	3e-06	1.37e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	3e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—hematologic cancer	2.99e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.99e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—hematologic cancer	2.99e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—hematologic cancer	2.98e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.96e-06	1.35e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.96e-06	1.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.95e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.94e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.94e-06	1.34e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—hematologic cancer	2.94e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.94e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.93e-06	1.33e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—hematologic cancer	2.91e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.91e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.9e-06	1.32e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	2.89e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.88e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.88e-06	1.31e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.88e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.88e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.88e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—hematologic cancer	2.86e-06	1.3e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.8e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—hematologic cancer	2.8e-06	1.27e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—hematologic cancer	2.8e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.78e-06	1.27e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.77e-06	1.26e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—hematologic cancer	2.77e-06	1.26e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.76e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.75e-06	1.25e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.75e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—hematologic cancer	2.74e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—hematologic cancer	2.74e-06	1.25e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.72e-06	1.24e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2.72e-06	1.24e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—hematologic cancer	2.71e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.71e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—hematologic cancer	2.71e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—hematologic cancer	2.68e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—hematologic cancer	2.68e-06	1.22e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—hematologic cancer	2.68e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	2.67e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.67e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.66e-06	1.21e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.66e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—hematologic cancer	2.65e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—hematologic cancer	2.62e-06	1.19e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	2.59e-06	1.18e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—hematologic cancer	2.56e-06	1.17e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.55e-06	1.16e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.55e-06	1.16e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	2.54e-06	1.16e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.5e-06	1.14e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.48e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—hematologic cancer	2.48e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	2.48e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—hematologic cancer	2.47e-06	1.13e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—hematologic cancer	2.46e-06	1.12e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	2.45e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	2.45e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.44e-06	1.11e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—hematologic cancer	2.42e-06	1.1e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—hematologic cancer	2.42e-06	1.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.37e-06	1.08e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—hematologic cancer	2.36e-06	1.08e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.35e-06	1.07e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—hematologic cancer	2.35e-06	1.07e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—hematologic cancer	2.31e-06	1.05e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.3e-06	1.05e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	2.29e-06	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.27e-06	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.26e-06	1.03e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.25e-06	1.02e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—hematologic cancer	2.25e-06	1.02e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—hematologic cancer	2.22e-06	1.01e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—hematologic cancer	2.21e-06	1.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—hematologic cancer	2.2e-06	1e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.18e-06	9.93e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—hematologic cancer	2.17e-06	9.87e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—hematologic cancer	2.15e-06	9.8e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	2.1e-06	9.58e-06	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—hematologic cancer	2.08e-06	9.45e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.06e-06	9.38e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—hematologic cancer	2.04e-06	9.3e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—hematologic cancer	2.01e-06	9.17e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	2e-06	9.1e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.9e-06	8.65e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.86e-06	8.46e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—hematologic cancer	1.64e-06	7.48e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—EP300—hematologic cancer	1.57e-06	7.13e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.16e-06	5.28e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—hematologic cancer	9.47e-07	4.31e-06	CbGpPWpGaD
